alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 375 studies published 2023 · free to read (page 6 of 15) · 30,580 in the whole library · How the 0–100 score works

Download bibliography of these 375 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,054 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Science (New York, N.Y.) 2023-03-16

Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association Between Socioeconomic Factors, Race, and Use of a Specialty Memory Clinic

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2023-08-02

4,824 patients seen at the memory clinic between 2008-2018 were included in this study (mean age 72.7 [standard deviation 11.0] years, 2,712 [56%] female, 543 [11%] Black). 5 key findings →

Design: cross-sectional Participants: 4,824 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Evaluation of Neighborhood-Level Disadvantage and Cognition in Mexican American and Non-Hispanic White Adults 50 Years and Older in the US

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA Network Open 2023-08-30

Among 1614 older adults (mean [SD] age, 66.3 [8.7] years; 980 women [60.7%]), 853 were Mexican American (mean [SD] age, 63.9 [7.9] years; 566 women [66.4%]), and 761 were non-Hispanic White (mean [SD] age, 69.1 [8.7] years; 414 women [54.4%]). 5 key findings →

Design: cross-sectional Participants: 280 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Blood β-synuclein is related to amyloid PET positivity in memory clinic patients

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-04-13

Plasma β-synuclein demonstrated discriminative properties for Aβ PET positive and negative subjects. 3 key findings →

Design: longitudinal study Participants: 51 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2023-12-28

Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. 4 key findings →

Design: clinical trial Participants: 1,691 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Platelet factors attenuate inflammation and rescue cognition in ageing

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Nature 2023-08-16

Identifying therapeutics to delay, and potentially reverse, age-related cognitive decline is critical in light of the increased incidence of dementia-related disorders forecasted in the growing older population 1 . 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Plasma biomarkers for prediction of Alzheimer's disease neuropathologic change

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Acta neuropathologica 2023-06-03

While plasma biomarkers for Alzheimer's disease (AD) are increasingly being evaluated for clinical diagnosis and prognosis, few population-based autopsy studies have evaluated their utility in the context of predicting neuropathological changes. 3 key findings →

Participants: 350 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Does Therapeutic Exercise Support Improvement in Cognitive Function and Instrumental Activities of Daily Living in Patients with Mild Alzheimer's Disease? A Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Brain sciences 2023-07-22

This randomized controlled trial aims to investigate the effect of 12 weeks of therapeutic exercise on cognitive function and daily activities in patients with mild Alzheimer's disease (AD). 4 key findings →

Design: randomized controlled trial Participants: 57 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A Web-Based Decision Aid for Caregivers of Persons With Dementia With Firearm Access (Safe at Home Study): Protocol for a Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 58 out of 100. JMIR research protocols 2023-01-31

The S@H study is the first randomized trial of a firearm safety decision aid for ADRD caregivers. 3 key findings →

Design: randomized controlled trial Participants: 117 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A Randomized Double-blind Study to Assess the Skin Irritation and Sensitization Potential of a Once-weekly Donepezil Transdermal Delivery System in Healthy Volunteers

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Alzheimer disease and associated disorders 2023-09-11

Once-weekly 5-mg/d donepezil TDS demonstrated minimal skin irritation under conditions of use of 3 consecutive weekly patch applications to the same skin site and minimal sensitization potential. 2 key findings →

Design: clinical trial Participants: 198 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Molecular neurodegeneration 2023-07-29

Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Implications of gut and oral microbiota in neuroinflammatory responses in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Life sciences 2023-10-02

A diverse and stable microbiota promotes a healthy state, nevertheless, an imbalance in gut or oral bacterial composition, called dysbiosis, can cause gastrointestinal disorders, systemic inflammatory states and oxidative stress, among others. 5 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Acta neuropathologica communications 2023-04-26

Amyloid PET imaging has been crucial for detecting the accumulation of amyloid beta (Aβ) deposits in the brain and to study Alzheimer's disease (AD). 4 key findings →

Participants: 13,409 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 2023-04-21

Our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD. 2 key findings →

Design: cross-sectional Participants: 25 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The clinical efficacy of Olibanum gum chewing in patients with Mild-to-Moderate Alzheimer disease: A randomized Parallel-Design controlled trial

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neuropsychopharmacology reports 2023-12-08

This study revealed that 18 weeks of gum chewing with Olibanum did not change the neuropsychological status. 5 key findings →

Participants: 36 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The structural and social determinants of Alzheimer's disease related dementias

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-04-19

Under Bronfenbrenner's macrosystem framework, we highlight key quantitative and qualitative studies linking S/SDOH with AD/ADRD, identify scientific gaps in the literature, and propose guidance for future research. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events